{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:33:33Z","timestamp":1759775613965},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T00:00:00Z","timestamp":1437091200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12929-015-0163-x","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T11:43:30Z","timestamp":1437047010000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines"],"prefix":"10.1186","volume":"22","author":[{"given":"Samuel","family":"Troadec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lina","family":"Blairvacq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassima","family":"Oumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Galons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Berthou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,17]]},"reference":[{"key":"163_CR1","first-page":"85","volume":"25","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85\u2013109.","journal-title":"J Natl Cancer Inst"},{"key":"163_CR2","doi-asserted-by":"crossref","unstructured":"Melo JV, Chuah C. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Hematology Am Soc Hematol Educ Program. 2008;427\u2013435.","DOI":"10.1182\/asheducation-2008.1.427"},{"key":"163_CR3","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to sti-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science. 2001;293:876\u201380.","journal-title":"Science"},{"key":"163_CR4","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","volume":"101","author":"FX Mahon","year":"2003","unstructured":"Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, et al. Mdr1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101:2368\u201373.","journal-title":"Blood"},{"key":"163_CR5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/sj.leu.2405086","volume":"22","author":"H Konig","year":"2008","unstructured":"Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ, et al. Enhanced bcr-abl kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in cmL progenitors. Leukemia. 2008;22:748\u201355.","journal-title":"Leukemia"},{"key":"163_CR6","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","volume":"68","author":"FX Mahon","year":"2008","unstructured":"Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, et al. Evidence that resistance to nilotinib may be due to bcr-abl, pgp, or src kinase overexpression. Cancer Res. 2008;68:9809\u201316.","journal-title":"Cancer Res"},{"key":"163_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","volume":"1","author":"M Sattler","year":"2002","unstructured":"Sattler M, Golam Mohi M, Pride YB, Quinnan LR, Malouf NA, Podar K, et al. Critical role for gab2 in transformation by bcr\/abl. Cancer Cell. 2002;1:479\u201392.","journal-title":"Cancer Cell"},{"key":"163_CR8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/sj.onc.1205202","volume":"21","author":"M Sattler","year":"2002","unstructured":"Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H, et al. Differential expression and signaling of cbl and cbl-b in bcr\/abl transformed cells. Oncogene. 2002;21:1423\u201333.","journal-title":"Oncogene"},{"key":"163_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev.cellbio.13.1.261","volume":"13","author":"DO Morgan","year":"1997","unstructured":"Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 1997;13:261\u201391.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"163_CR10","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1126\/science.7997877","volume":"266","author":"LH Hartwell","year":"1994","unstructured":"Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266:1821\u20138.","journal-title":"Science"},{"key":"163_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/13543784.14.4.457","volume":"14","author":"PM Fischer","year":"2005","unstructured":"Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs. 2005;14:457\u201377.","journal-title":"Expert Opin Investig Drugs"},{"key":"163_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.gde.2006.12.008","volume":"17","author":"M Malumbres","year":"2007","unstructured":"Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev. 2007;17:60\u20135.","journal-title":"Curr Opin Genet Dev"},{"key":"163_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1021\/ar0201198","volume":"36","author":"L Meijer","year":"2003","unstructured":"Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. from starfish oocytes to clinical trials. Acc Chem Res. 2003;36:417\u201325.","journal-title":"Acc Chem Res"},{"key":"163_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","volume":"243","author":"L Meijer","year":"1997","unstructured":"Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997;243:527\u201336.","journal-title":"Eur J Biochem"},{"key":"163_CR15","first-page":"1311","volume":"5","author":"T Guzi","year":"2004","unstructured":"Guzi T. Cyc-202 cyclacel. Curr Opin Investig Drugs. 2004;5:1311\u20138.","journal-title":"Curr Opin Investig Drugs"},{"key":"163_CR16","doi-asserted-by":"publisher","first-page":"31208","DOI":"10.1074\/jbc.M500806200","volume":"280","author":"S Bach","year":"2005","unstructured":"Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem. 2005;280:31208\u201319.","journal-title":"J Biol Chem"},{"key":"163_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ijc.10738","volume":"102","author":"SJ McClue","year":"2002","unstructured":"McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor cyc202 (r-roscovitine). Int J Cancer. 2002;102:463\u20138.","journal-title":"Int J Cancer"},{"key":"163_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.bjc.6603509","volume":"96","author":"C Benson","year":"2007","unstructured":"Benson C, White J, De Bono J, O\u2019Donnell A, Raynaud F, Cruickshank C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (cyc202; r-roscovitine), administered twice daily for 7\u00a0days every 21\u00a0days. Br J Cancer. 2007;96:29\u201337.","journal-title":"Br J Cancer"},{"key":"163_CR19","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1021\/jm800109e","volume":"51","author":"N Oumata","year":"2008","unstructured":"Oumata N, Bettayeb K, Ferandin Y, Demange L, Lopez-Giral A, Goddard ML, et al. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J Med Chem. 2008;51:5229\u201342.","journal-title":"J Med Chem"},{"key":"163_CR20","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1038\/onc.2008.191","volume":"27","author":"K Bettayeb","year":"2008","unstructured":"Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008;27:5797\u2013807.","journal-title":"Oncogene"},{"key":"163_CR21","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1038\/onc.2013.513","volume":"33","author":"C Delehouz\u00e9","year":"2014","unstructured":"Delehouz\u00e9 C, Godl K, Loa\u00ebc N, Bruy\u00e8re C, Desban N, Oumata N, et al. Cdk\/ck1 inhibitors roscovitine and cr8 downregulate amplified mycn in neuroblastoma cells. Oncogene. 2014;33:5675\u201387.","journal-title":"Oncogene"},{"key":"163_CR22","doi-asserted-by":"crossref","unstructured":"Meijer L, Bettayeb K, Galons H. Roscovitine (cyc202, seliciclib). In: Smith P, Yue E, editors. Monographs on enzyme inhibitors. CRC Press, Taylor & Francis, 2006;187\u2013226.","DOI":"10.1201\/9781420005400.ch9"},{"key":"163_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0039-6060(97)90008-8","volume":"122","author":"H Iseki","year":"1997","unstructured":"Iseki H, Ko TC, Xue XY, Seapan A, Hellmich MR, Townsend Jr CM. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Surgery. 1997;122:187\u201395.","journal-title":"Surgery"},{"key":"163_CR24","first-page":"3689","volume":"60","author":"CJ Sherr","year":"2000","unstructured":"Sherr CJ. The pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000;60:3689\u201395.","journal-title":"Cancer Res"},{"key":"163_CR25","first-page":"4301","volume":"61","author":"MV Blagosklonny","year":"2001","unstructured":"Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 2001;61:4301\u20135.","journal-title":"Cancer Res"},{"key":"163_CR26","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1158\/0008-5472.CAN-05-0233","volume":"65","author":"DE MacCallum","year":"2005","unstructured":"MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, et al. Seliciclib (cyc202, r-roscovitine) induces cell death in multiple myeloma cells by inhibition of rna polymerase ii-dependent transcription and down-regulation of mcl-1. Cancer Res. 2005;65:5399\u2013407.","journal-title":"Cancer Res"},{"key":"163_CR27","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/prot.21370","volume":"67","author":"G Lolli","year":"2007","unstructured":"Lolli G, Johnson LN. Recognition of cdk2 by cdk7. Proteins. 2007;67:1048\u201359.","journal-title":"Proteins"},{"key":"163_CR28","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1046\/j.1432-1327.2000.01455.x","volume":"267","author":"P Kaldis","year":"2000","unstructured":"Kaldis P, Solomon MJ. Analysis of cak activities from human cells. Eur J Biochem. 2000;267:4213\u201321.","journal-title":"Eur J Biochem"},{"key":"163_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/sj.leu.2402337","volume":"16","author":"VM Dirsch","year":"2002","unstructured":"Dirsch VM, Antlsperger DSM, Hentze H, Vollmar AM. Ajoene, an experimental anti-leukemic drug: mechanism of cell death. Leukemia. 2002;16:74\u201383.","journal-title":"Leukemia"},{"key":"163_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/jcb.1155","volume":"82","author":"J Wu","year":"2001","unstructured":"Wu J, Suzuki H, Zhou YW, Liu W, Yoshihara M, Kato M, et al. Cepharanthine activates caspases and induces apoptosis in jurkat and k562 human leukemia cell lines. J Cell Biochem. 2001;82:200\u201314.","journal-title":"J Cell Biochem"},{"key":"163_CR31","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1074\/jbc.274.8.5053","volume":"274","author":"XM Sun","year":"1999","unstructured":"Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem. 1999;274:5053\u201360.","journal-title":"J Biol Chem"},{"key":"163_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1083\/jcb.136.1.215","volume":"136","author":"NJ McCarthy","year":"1997","unstructured":"McCarthy NJ, Whyte MK, Gilbert CS, Evan GI. Inhibition of ced-3\/ice-related proteases does not prevent cell death induced by oncogenes, dna damage, or the bcl-2 homologue bak. J Cell Biol. 1997;136:215\u201327.","journal-title":"J Cell Biol"},{"key":"163_CR33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0092-8674(00)81728-6","volume":"94","author":"DR Green","year":"1998","unstructured":"Green DR. Apoptotic pathways: the roads to ruin. Cell. 1998;94:695\u20138.","journal-title":"Cell"},{"key":"163_CR34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/bj3150021","volume":"315","author":"EA Slee","year":"1996","unstructured":"Slee EA, Zhu H, Chow SC, MacFarlane M, Nicholson DW, Cohen GM. Benzyloxycarbonyl-val-ala-asp (ome) fluoromethylketone (z-vad.fmk) inhibits apoptosis by blocking the processing of cpp32. Biochem J. 1996;315:21\u20134.","journal-title":"Biochem J"},{"key":"163_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/17135","volume":"397","author":"SA Susin","year":"1999","unstructured":"Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397:441\u20136.","journal-title":"Nature"},{"key":"163_CR36","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1158\/1535-7163.MCT-08-0655","volume":"7","author":"X Garrof\u00e9-Ochoa","year":"2008","unstructured":"Garrof\u00e9-Ochoa X, Melero-Fern\u00e1ndez de Mera RM, Fern\u00e1ndez-G\u00f3mez FJ, Ribas J, Jord\u00e1n J, Boix J. Bax and bak proteins are required for cyclin-dependent kinase inhibitory drugs to cause apoptosis. Mol Cancer Ther. 2008;7:3800\u20136.","journal-title":"Mol Cancer Ther"},{"key":"163_CR37","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1101\/gad.1093903","volume":"17","author":"D Nijhawan","year":"2003","unstructured":"Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, et al. Elimination of mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003;17:1475\u201386.","journal-title":"Genes Dev"},{"key":"163_CR38","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1158\/1078-0432.CCR-12-2170","volume":"19","author":"E Cosimo","year":"2013","unstructured":"Cosimo E, McCaig AM, Carter-Brzezinski LJM, Wheadon H, Leach MT, Le Ster K, et al. Inhibition of nf-\u03bab-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells. Clin Cancer Res. 2013;19:2393\u2013405.","journal-title":"Clin Cancer Res"},{"key":"163_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1947601910369817","volume":"1","author":"K Bettayeb","year":"2010","unstructured":"Bettayeb K, Baunb\u00e6k D, Delehouze C, Loa\u00ebc N, Hole AJ, Baumli S, et al. Cdk inhibitors roscovitine and cr8 trigger mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells. Genes Cancer. 2010;1:369\u201380.","journal-title":"Genes Cancer"},{"key":"163_CR40","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1182\/blood-2005-01-0320","volume":"106","author":"N Raje","year":"2005","unstructured":"Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, et al. Seliciclib (cyc202 or r-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of mcl-1 in multiple myeloma. Blood. 2005;106:1042\u20137.","journal-title":"Blood"},{"key":"163_CR41","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/sj.onc.1207205","volume":"23","author":"Y Zheng","year":"2004","unstructured":"Zheng Y, Shi Y, Tian C, Jiang C, Jin H, Chen J, et al. Essential role of the voltage-dependent anion channel (vdac) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene. 2004;23:1239\u201347.","journal-title":"Oncogene"},{"key":"163_CR42","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1128\/MCB.00165-10","volume":"30","author":"N Keinan","year":"2010","unstructured":"Keinan N, Tyomkin D, Shoshan-Barmatz V. Oligomerization of the mitochondrial protein voltage-dependent anion channel is coupled to the induction of apoptosis. Mol Cell Biol. 2010;30:5698\u2013709.","journal-title":"Mol Cell Biol"},{"key":"163_CR43","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/blood-2012-06-440230","volume":"122","author":"B Koss","year":"2013","unstructured":"Koss B, Morrison J, Perciavalle RM, Singh H, Rehg JE, Williams RT, et al. Requirement for antiapoptotic mcl-1 in the survival of bcr-abl b-lineage acute lymphoblastic leukemia. Blood. 2013;122:1587\u201398.","journal-title":"Blood"},{"key":"163_CR44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/35080103","volume":"2","author":"M Holcik","year":"2001","unstructured":"Holcik M, Korneluk RG. Xiap, the guardian angel. Nat Rev Mol Cell Biol. 2001;2:550\u20136.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"163_CR45","first-page":"5315","volume":"58","author":"I Tamm","year":"1998","unstructured":"Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. Iap-family protein survivin inhibits caspase activity and apoptosis induced by fas (cd95), bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315\u201320.","journal-title":"Cancer Res"},{"key":"163_CR46","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/sj.onc.1208350","volume":"24","author":"H Caldas","year":"2005","unstructured":"Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene. 2005;24:1994\u20132007.","journal-title":"Oncogene"},{"key":"163_CR47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fonc.2014.00197","volume":"4","author":"P Obexer","year":"2014","unstructured":"Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol. 2014;4:197.","journal-title":"Front Oncol"},{"key":"163_CR48","first-page":"589","volume":"23","author":"A Badran","year":"2003","unstructured":"Badran A, Yoshida A, Wano Y, Imamura S, Kawai Y, Tsutani H, et al. Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res. 2003;23:589\u201392.","journal-title":"Anticancer Res"},{"key":"163_CR49","first-page":"899","volume":"21","author":"J Zhao","year":"2013","unstructured":"Zhao J, Ma LM. Effect of bortezomib on reverse multidrug resistance and xiap expression in imatinib-resistant primary cells of chronic myeloid leukemia in blastic crisis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21:899\u2013904.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"163_CR50","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.leukres.2013.06.014","volume":"37","author":"KL Silva","year":"2013","unstructured":"Silva KL, Silva de Souza P, Nestal de Moraes G, Moellmann-Coelho A, da Cunha Vasconcelos F, Ciuvalschi Maia R. Xiap and p-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells. Leuk Res. 2013;37:1350\u20138.","journal-title":"Leuk Res"},{"key":"163_CR51","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/sj.cdd.4400944","volume":"8","author":"G Loo van","year":"2001","unstructured":"van Loo G, Schotte P, van Gurp M, Demol H, Hoorelbeke B, Gevaert K, et al. Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent dna degradation. Cell Death Differ. 2001;8:1136\u201342.","journal-title":"Cell Death Differ"},{"key":"163_CR52","first-page":"1143","volume":"10","author":"DW Hedley","year":"1996","unstructured":"Hedley DW, McCulloch EA. Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2. Leukemia. 1996;10:1143\u20139.","journal-title":"Leukemia"},{"key":"163_CR53","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s10495-010-0512-x","volume":"15","author":"BM Kim","year":"2010","unstructured":"Kim BM, Choi YJ, Lee YH, Joe YA, Hong SH. N, n-dimethyl phytosphingosine sensitizes hl-60\/mx2, a multidrug-resistant variant of hl-60 cells, to doxorubicin-induced cytotoxicity through ros-mediated release of cytochrome c and AIF. Apoptosis. 2010;15:982\u201393.","journal-title":"Apoptosis"},{"key":"163_CR54","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1074\/jbc.275.10.7337","volume":"275","author":"M Schuler","year":"2000","unstructured":"Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem. 2000;275:7337\u201342.","journal-title":"J Biol Chem"},{"key":"163_CR55","first-page":"4","volume":"7","author":"RC Jackson","year":"2013","unstructured":"Jackson RC, Radivoyevitch T. Modelling c-abl signalling in activated neutrophils: the anti-inflammatory effect of seliciclib. Biodiscovery. 2013;7:4.","journal-title":"Biodiscovery"},{"key":"163_CR56","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00726-011-1040-x","volume":"42","author":"ED Arsan","year":"2012","unstructured":"Arsan ED, Coker A, Palavan-\u00dcnsal N. Polyamine depletion enhances the roscovitine-induced apoptosis through the activation of mitochondria in hct116 colon carcinoma cells. Amino Acids. 2012;42:655\u201365.","journal-title":"Amino Acids"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12929-015-0163-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-015-0163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-015-0163-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-015-0163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T08:57:20Z","timestamp":1566982640000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-015-0163-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,17]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["163"],"URL":"https:\/\/doi.org\/10.1186\/s12929-015-0163-x","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,17]]},"assertion":[{"value":"10 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"57"}}